Risk of cardiovascular toxicities and hypertension in nonmetastatic castration-resistant prostate cancer patients treated with novel hormonal agents: a systematic review and meta-analysis

References

• Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021 May;71(3):209–249. Epub 2021 Feb 4. PMID: 33538338.
   PubMed Web of Science ®Google Scholar
• Van den Broeck T, van den Bergh RCN, Arfi N, et al. Prognostic Value of Biochemical Recurrence Following Treatment with Curative Intent for Prostate Cancer: A Systematic Review. Eur Urol. 2019;75(6):967–987.
   PubMed Web of Science ®Google Scholar
• Mollica V, Rizzo A, Massari F. The pivotal role of TMPRSS2 in coronavirus disease 2019 and prostate cancer. Future Oncol. 2020 Sep;16(27):2029–2033. Epub 2020 Jul 13. PMID: 32658591; PMCID: PMC7359420.
   PubMed Web of Science ®Google Scholar
• Smith MR, Kabbinavar F, Saad F, et al. Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer. J Clin Oncol. 2005;23(13):2918–2925.
   PubMed Web of Science ®Google Scholar
• Hussain M, Fizazi K, Saad F, et al. Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer. N Engl J Med. 2018;378(26): 2465–2474.
   PubMed Web of Science ®Google Scholar
• Smith MR, Saad F, Chowdhury S, et al. Apalutamide treatment and metastasis-free survival in prostate cancer. N Engl J Med. 2018;378(15): 1408–1418.
   PubMed Web of Science ®Google Scholar
• Fizazi K, Shore N, Tammela TL, et al. Darolutamide in nonmetastatic, castration-resistant prostate cancer. N Engl J Med. 2019;380(13): 1235–1246.
   PubMed Web of Science ®Google Scholar
• Sternberg CN, Fizazi K, Saad F, et al. Enzalutamide and survival in nonmetastatic, castration-resistant prostate cancer. N Engl J Med. 2020;382(23): 2197–2206.
   PubMed Web of Science ®Google Scholar
• Small EJ, Saad F, Chowdhury S, et al. Apalutamide and overall survival in non-metastatic castration-resistant prostate cancer. Ann Oncol. 2019;30(11):1813–1820.
   PubMed Web of Science ®Google Scholar
• Fizazi K, Shore N, Tammela TL, et al. Nonmetastatic, castration-resistant prostate cancer and survival with darolutamide. N Engl J Med. 2020 Sep 10 383;(11)1040–1049.
   PubMed Web of Science ®Google Scholar
• Saigal CS, Gore JL, Krupski TL, et al. Urologic Diseases in America Project. Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer. Cancer. 2007 Oct 1;110(7):1493–1500. PMID: 17657815.
   PubMed Web of Science ®Google Scholar
• Lu-Yao G, Stukel TA, Yao SL. Changing patterns in competing causes of death in men with prostate cancer: a population based study. J Urol. 2004 Jun;171(6 Part 1):2285–2290. PMID: 15126804.
   PubMed Web of Science ®Google Scholar
• O’Farrell S, Garmo H, Holmberg L, et al. Risk and timing of cardiovascular disease after androgen-deprivation therapy in men with prostate cancer. J Clin Oncol. 2015 Apr 10;33(11):1040–1049. Epub 2015 Mar 2. PMID: 25732167.
   PubMed Web of Science ®Google Scholar
• Veccia A, Maines F, Kinspergher S, et al. Cardiovascular toxicities of systemic treatments of prostate cancer. Nat Rev Urol. 2017 Jan 24;14(4):230–243. Epub ahead of print. PMID: 28117849.
   PubMed Web of Science ®Google Scholar
• Del Re M, Fogli S, Derosa L, et al. The role of drug-drug interactions in prostate cancer treatment: focus on abiraterone acetate/ prednisone and enzalutamide. Cancer Treat Rev. 2017 Apr;55:71–82. Epub 2017 Mar 9. PMID: 28340451.
   PubMed Web of Science ®Google Scholar
• Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4(1):1.
   PubMed Web of Science ®Google Scholar
• Higgins J, Green S. Cochrane handbook for systematic reviews of interventions version 5.1.0 [updated March 2011]. Cochrane Collab, 2011.
   Google Scholar
• Esther J, Maughan BL, Anderson N, et al. Management of nonmetastatic castration-resistant prostate cancer: recent advances and future direction. Curr Treat Options Oncol. 2019;20(2):14.
   PubMed Web of Science ®Google Scholar
• Papazoglou P, Peng L, Sachinidis A. Epigenetic mechanisms involved in the cardiovascular toxicity of anticancer drugs. Front Cardiovasc Med. 2021 Apr 27;8:658900.
   PubMed Web of Science ®Google Scholar
• Lyon AR, Yousaf N, Battisti NML, et al. Immune checkpoint inhibitors and cardiovascular toxicity. Lancet Oncol. 2018 Sep;19(9):e447–e458. PMID: 30191849.
   PubMed Web of Science ®Google Scholar
• Massari F, Mollica V, Rizzo A, et al. Safety evaluation of immune-based combinations in patients with advanced renal cell carcinoma: a systematic review and meta-analysis. Expert Opin Drug Saf. 2020 Oct;19(10):1329–1338. Epub 2020 Sep 8. PMID: 32799582.
   PubMed Web of Science ®Google Scholar
• Reck M, Rodríguez-Abreu D, Robinson AG, et al. KEYNOTE-024 Investigators. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2016 Nov 10;375(19):1823–1833. Epub 2016 Oct 8. PMID: 27718847.
   PubMed Web of Science ®Google Scholar
• Santoni M, Buti S, Conti A, et al. Prognostic significance of host immune status in patients with late relapsing renal cell carcinoma treated with targeted therapy. Target Oncol. 2015 Dec;10(4):517–522. Epub 2015 Jan 6. PMID: 25559290.
   PubMed Web of Science ®Google Scholar
• Beyer AM, Bonini MG, Moslehi J. Cancer therapy-induced cardiovascular toxicity: old/new problems and old drugs. Am J PhysiolHeart Circ Physiol. 2019 Jul 1;317(1):H164–H167. Epub 2019 Jun 7. PMID: 31172808; PMCID: PMC6692734.
   PubMed Web of Science ®Google Scholar
• Kim CW, Choi KC. Effects of anticancer drugs on the cardiac mitochondrial toxicity and their underlying mechanisms for novel cardiac protective strategies. Life Sci. 2021 May 13;277:119607.
   PubMed Web of Science ®Google Scholar
• Nonaka M, Hosoda H, Uezono Y. Cancer treatment-related cardiovascular disease: current status and future research priorities. Biochem Pharmacol. 2021 May;190:114599. Epub ahead of print. PMID: 33989656.
   PubMed Web of Science ®Google Scholar
• Lokeshwar SD, Klaassen Z, Saad F. Treatment and trials in non-metastatic castration-resistant prostate cancer. Nat Rev Urol. 2021 May 17;18(7):433–442. Epub ahead of print. PMID: 34002069.
   PubMed Web of Science ®Google Scholar
• Wang L, Paller C, Hong H, et al. Comparison of treatments for nonmetastatic castration-resistant prostate cancer: matching-adjusted indirect comparison and network meta-analysis. J Natl Cancer Inst. 2021 Apr;8:djab071. Epub ahead of print. PMID: 33830214.
   Google Scholar
• Halabi S, Jiang S, Terasawa E, et al. Indirect comparison of darolutamide versus apalutamide and enzalutamide for nonmetastatic castration-resistant prostate cancer. J Urol. 2021 Apr;5:101097JU0000000000001767. Epub ahead of print. PMID: 33818140.
   Google Scholar